A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants
Pace D., Snape M., Westcar S., Hamaluba M., Yu LM., Begg N., Wysocki J., Czajka H., Maechler G., Boutriau D., Pollard AJ.
We conducted a phase 3 randomized controlled trial looking at the immunogenicity and safety of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C tetanus toxoid conjugate vaccine, Hib-MenC-TT in a 2-, 3-, and 4-month primary infant immunization schedule. SBA MenC titers ≥1:8 and anti-PRP concentrations ≥0.15 μg/mL were measured in 99.2% and 100%, respectively, of the infants receiving Hib-MenC-TT. © 2007 Lippincott Williams & Wilkins, Inc.